Download PDF
Adipositas - Ursachen, Folgeerkrankungen, Therapie 2007; 01(02): 95-99
DOI: 10.1055/s-0037-1618615
Hypertonie bei Adipositas
Schattauer GmbH

Differenzierte Pharmakotherapie beim adipösen Hypertoniker

Differential therapy of obesity-associated hypertension
J. Scholze
1   Universitätsmedizin Berlin, Charité, Medizinische Poliklinik/Ambulante Spezialmedizin/CCM (Direktor: Prof. Dr. J. Scholze)
› Author Affiliations
Further Information

Publication History

Publication Date:
21 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Adipositas geht mit einer ca. 50%igen Prävalenz hypertoner Blutdruckwerte einher, die in Abhängigkeit vom Body-Mass-Index bis auf 80 Prozent ansteigt. Primäres Ziel ist eine durch Ernährungs-und Life-style-Modifikation erzielte, lang anhaltende Gewichtsreduktion, welche gegebenenfalls mit gewichtsreduzierenden Medikamenten zu ergänzen sind. Dabei senkt Orlistat zugleich den Blutdruck, was vom Sibutramin nur unter bestimmten Voraussetzungen in speziellen Situationen ausgeht. Die antihypertensive medikamentöse Differenzialtherapie sollte sich am pathophysiologischen Realisierungsmuster und den Begleit-und Folgeerkrankungen orientieren. Dabei genießen ACE-Hemmer (alternativ Angiotensin-Rezeptor-Blocker) in Kombination mit niedrig dosierten Diuretika die Priorität, gefolgt in der Kombination mit Kalziumantagonisten. Beta-Rezeptoren-Blocker sollten immer dann zum Einsatz kommen, wenn eindeutige kardiale Indikationen bestehen.

Summary

There is a 50% prevalence of obesity with arterial hypertension. This ratio can increase up to 80 %, depending on body mass index. The primary therapeutic aim is a reduction in weight by means of a balanced diet and life style modification, which can be augmented by weight reducing medication. Orlistat lowers blood pressure and body weight simultaneously, whereas sibutramine accomplishes this only under certain circumstances. Antihypertensive differential therapy should be focused on pathophysiology and concomitant and target organ disease. Thus ACE inhibitors (alternatively Angiotensin Receptor Blockers), in combination with low dose diuretics, should be preferentially administered, followed by calcium antagonists. Beta blockers should only be used if definite cardiac indications are present.

Schlüsselwörter

Adipositas - Hypertonie - antihypertensive Therapie

Keywords

Obesity - hypertension - antihypertensive treatment
 

  • Literatur

  • 1 Alpert MA, Lambert CR, Terry BE. et al. Interrelationsship of left ventricular mass, systolic function and diastolic filling in normotensive morbidly obese patients. Int J Obes 1995; 19: 550-557.
    PubMedGoogle Scholar
  • 2 Bakris G, Calhoun D, Egan B. et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertension 2002; 20: 2257-2267.
    CrossrefPubMedGoogle Scholar
  • 3 Birkenfeld AL, Schroeder CH, Pischon T. et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients. Sibutramine and blood pressure. Clin Auton Res 2005; 15: 200-206.
    CrossrefPubMedGoogle Scholar
  • 4 Bramlage P, Pittrow D, Wittchen HU. et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17 (10) 904-910.
    CrossrefPubMedGoogle Scholar
  • 5 Derosa G, Cicero AFG, Murdolo G. et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes, Obesity and Metabolism 2005; 07: 47-55.
    CrossrefPubMedGoogle Scholar
  • 6 Douketis JD, Sharma AM. The Management of hypertension in the overweight and obese patient. Is weight reduction sufficient? Drugs 2004; 64 (08) 795-803.
    PubMedGoogle Scholar
  • 7 Epstein M. Calcium antagonists and the kidney. J Cardiovasc Pharmacol 1994; 24 (Suppl A): S18-S24.
    PubMedGoogle Scholar
  • 8 Fogari R, Zoppi A, Lazzari P. et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32: 616-620.
    CrossrefPubMedGoogle Scholar
  • 9 Gress TW, Nieto FJ, Shahar E. et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
    CrossrefPubMedGoogle Scholar
  • 10 Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80: 1453-1458.
    CrossrefPubMedGoogle Scholar
  • 11 Hu FB, Willett WC, Li T. et al. Adiposity as compared with physical activity in predicting mortality among woman. N Engl J Med 2004; 351: 2694-2703.
    CrossrefPubMedGoogle Scholar
  • 12 James WP, Astrup A, Finer N. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119-2225.
    CrossrefPubMedGoogle Scholar
  • 13 Jordan J, Scholze J, Matiba B. et al. Influence of sibutramine in blood pressure: evidence from placebo-controlled trials. InternJ Obes 2005; 29: 1-8.
    PubMedGoogle Scholar
  • 14 Kortelainen ML, Särkioia T. Extent and composition of coronary lesions and degree of cardiac hypertrophy in relation to abdominal fatness in men under 40 years of age. Arterioscler Thromb Vasc Biol 1997; 17: 574-579.
    CrossrefPubMedGoogle Scholar
  • 15 Lindholm LH, Ibsen H, Dahlöf B. et al. The LIFE Study Group. Cardiovascular morbidity and mortality in subjects with type 2 diabetes with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
    CrossrefPubMedGoogle Scholar
  • 16 Masuo K, Mikami H, Ogihara T. et al. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 2001; 14: 530-538.
    CrossrefPubMedGoogle Scholar
  • 17 Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987; 147: 1725-1728.
    CrossrefPubMedGoogle Scholar
  • 18 Morel Y, Gadient A, Keller U. et al. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995; 26: 306-311.
    CrossrefPubMedGoogle Scholar
  • 19 Pepine CJ, Handberg EM, Cooper-DeHoff RM. et al. INVEST Investigators: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial 2003; 290 (21) 2805-2816.
    PubMedGoogle Scholar
  • 20 Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
    CrossrefPubMedGoogle Scholar
  • 21 Reisin E, Weir MR, Falkner B. et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140-145.
    CrossrefPubMedGoogle Scholar
  • 22 Ruggenenti P, Fassi A, Ilieva AP. et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351 (19) 1941-1951.
    CrossrefPubMedGoogle Scholar
  • 23 Scholze J. Adipositasbehandlung mit Sibutramin unter Praxisbedingungen. Positive Effekte auf metabolische Parameter und Blutdruck. Dtsch Med Wochenschr 2002; 127: 605-610.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Scholze J, Grimm E, Herrmann D. et al. Optimal Treatment of Obesity-Related Hypertension -The Hypertension-Obesity-Sibutramine (HOS)-Study. Circulation 2007; 115 (15) 1991-1998.
    CrossrefPubMedGoogle Scholar
  • 25 Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 09: 1873-1878.
    PubMedGoogle Scholar
  • 26 Sharma AM, Pischon T, Hardt S. et al. Beta adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37 (02) 250-254.
    CrossrefPubMedGoogle Scholar
  • 27 Temelkova-Kurktschiev T, Schaper F, Kohler K. et al. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia 1998; 41 (06) 706-712.
    CrossrefPubMedGoogle Scholar
  • 28 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 255: 2981-2997.
    PubMedGoogle Scholar
  • 29 Torgerson JS, Boldrin MN, Hauptman J. et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care 2004; 27: 155-161.
    CrossrefPubMedGoogle Scholar
  • 30 Tuck ML, Sowers J, Dornfeld L. et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933.
    CrossrefPubMedGoogle Scholar
  • 31 van Gaal LF, Rissanen AM, Scheen A. et al. Effects of the cannabinoid-1-receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the Rio-Europe study. Lancet 2005; 365 9468 1389-1397.
    CrossrefPubMedGoogle Scholar
  • 32 2007 Guidelines for the management of arterial hypertension (ESC and ESH). Europ H J 2007; 28: 1462-1536.
    PubMed